Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene

Annals of the Rheumatic Diseases

Volumn 63, Issue 10, 2004, Pages 1227-1231

  Berkun, Y ^a   Levartovsky, D ^b   Rubinow, A ^c   Orbach, H ^a   Aamar, S ^c   Grenader, T ^c   Abou Atta, I ^c   Mevorach, D ^c   Friedman, G ^c   Ben Yehuda, A ^c  

^a BIKUR CHOLIM HOSPITAL   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; GENE PRODUCT; HOMOCYSTEINE; METHOTREXATE;

ABDOMINAL PAIN; ADULT; AGED; ALLELISM; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; INTERVIEW; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MTHFR GENE; NAUSEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN NODULE;

ADULT; AGED; ALLELES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 4644349995     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.016337     Document Type: Article

References (26)

1. Kremer JM. Methotrexate and emerging therapies. Rheum Dis Clin North Am 1998;24:651-8.
2. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
3. Cronstein BD. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
4. Goldman ID, Motherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985;28:77-102.
5. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11.
6. Roubenoff R, Dellaripa P, Nadeau MR, Abod LW, Muldoon BA, Selhub J, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthiritis Rheum 1997;40:718-22.
7. Hernanz A, Plaza A, Martin-Mola E, De Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999;32:65-70.
8. Morgan SL, Baggott JE, Refsum H, Ueland PM. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther 1991;50:547-56.
9. Haogsma G, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenrraij-Emmerzaal D, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentration in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
10. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441-6.
11. Van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658-65.
12. Jensen OK, Rasmussen C, Mollerup F, Christensen PB, Hansen H, Ekelund S, et al. Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation. J Rheumatol 2002;29:1615-18.
13. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al. Pharmacogenesis of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-4.
14. Toffoli G, Veronesi A, Boiocchi M, Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000;11:373-4.
15. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Mini E, et al. Effect of methylenetetrahydrofolate reductase 677CT polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003;103:294-9.
16. Van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CG, Thomas CM, et al. The C677T mutation in the methylenetetrahydrorolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
17. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Hakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmocogenetics 2002;12:183-90.
18. Van Der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trubels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Genet 1998;62:1044-51.
19. Weisberg I, Tran P, Christensen B, Sibani S, Rozen RI. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
20. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 1999;129:1656-61.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Van Riel PLCM. Provisional guidelines for measuring disease activity in RA clinical trials. Br J Rheumatol 1992;31:793-4.
23. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
24. Van Ede AE, Laan RF, Rood MJ, Huizinga TW, van der Laar MA, van Denderen O, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
25. Morgan SL, Baggot JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
26. Shpichinefsky V, Raz I, Friedlander Y, Goldschmidt N, Wexler I, Ben-Yehuda A, et al. The association between two common mutations C677T and Al 298C in human methylenetetrahydrofolate reductase gene the risk for diabetic nephropathy in type 2 diabetic patients. J Nutr 2000;130:2493-7.